Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CS-1 inhibitor

DRUG CLASS:

CS-1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

SLAMF7 FPBMC (0)

SLAMF7 FPBMC (0)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: B - Late Trials lenalidomide + elotuzumab Sensitive : B	lenalidomide + elotuzumab Sensitive: B - Late Trials lenalidomide + elotuzumab Sensitive : B
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
CCDC6-RET fusion	Colorectal Cancer	CCDC6-RET fusion	Colorectal Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
NCOA4-RET fusion	Non Small Cell Lung Cancer	NCOA4-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
EML4-RET fusion	Non Small Cell Lung Cancer	EML4-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
CD20 underexpression	Multiple Myeloma	CD20 underexpression	Multiple Myeloma	elotuzumab Resistant: D – Preclinical elotuzumab Resistant : D	elotuzumab Resistant: D – Preclinical elotuzumab Resistant : D
CCL20 underexpression	Multiple Myeloma	CCL20 underexpression	Multiple Myeloma	elotuzumab Sensitive: D – Preclinical elotuzumab Sensitive : D	elotuzumab Sensitive: D – Preclinical elotuzumab Sensitive : D